Dr. Paweł Wielgus, Eng., discusses his pursuit of the title of veterinary biotechnology leader in a new interview for FX MAG. The intense period of recent months has not only strengthened our basic assumptions but also yielded further conclusions. An example? “I just returned from the most important veterinary conference in Europe, and my thoughts are that we are witnessing the birth of a new, potentially multi-billion-dollar business area, alongside osteoarthritis and atopy. I’m referring to chronic kidney disease, also known as CKD. This applies to both dogs and cats. In the case of dogs, we have an idea how to leverage our current results and experience to accelerate the development of such a product. As for cats, this could be a good opportunity to launch a feline segment,” says Paweł Wielgus.
Read more: Polska spółka w 3 lata zostanie światowym liderem? Członek zarządu specjalnie dla FXMAG
MACHINE TRANSLATION